- Home
- BDCI vs PROK Comparison
BDCI vs PROK Comparison
Compare BDCI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$2.48
Company Overview
Basic Information| Metric | BDCI | PROK |
|---|---|---|
| Founded | 2023 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.8M | 331.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BDCI | PROK |
|---|---|---|
| Price | $10.00 | $2.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 16.8K | ★ 537.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,000.00 |
| Revenue This Year | N/A | $1,010.19 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.98 | $0.46 |
| 52 Week High | $10.20 | $7.13 |
Technical Indicators
Market Signals| Indicator | BDCI | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 34.88 | 62.25 |
| Support Level | N/A | $2.09 |
| Resistance Level | N/A | $2.58 |
| Average True Range (ATR) | 0.01 | 0.15 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 16.67 | 79.61 |
Price Performance
Historical Comparison BDCI
PROK
About BDCI BTC Development Corp. Class A Ordinary Shares
BTC Development Corp is a blank check company.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.